Mydecine Innovations Group Inc
Noveris Health Sciences Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. It also develops MYCO-005, MYCO-006, and MYCO-007 for MDMA and psilocybin analogs. The company has a partnership with Applied Pha… Read more
Mydecine Innovations Group Inc (MYCOF) - Total Liabilities
Latest total liabilities as of September 2025: $15.21 Million USD
Based on the latest financial reports, Mydecine Innovations Group Inc (MYCOF) has total liabilities worth $15.21 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mydecine Innovations Group Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Mydecine Innovations Group Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Mydecine Innovations Group Inc Competitors by Total Liabilities
The table below lists competitors of Mydecine Innovations Group Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eurobio Scientific Société anonyme
BE:E8TN
|
Germany | €141.16 Million |
|
Kure Technologies Inc
OTCGREY:UBSBF
|
USA | $1.85 Million |
|
Australian Bond Exchange Holdings Ltd
AU:ABE
|
Australia | AU$6.43 Million |
|
Handeni Gold Inc
PINK:HNDI
|
USA | $2.45 Million |
|
DELUXE
MU:DL8
|
Germany | €2.01 Billion |
|
Third Point Investors Limited
PINK:TPNTF
|
USA | $2.02 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Mydecine Innovations Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 322.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mydecine Innovations Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mydecine Innovations Group Inc (2012–2024)
The table below shows the annual total liabilities of Mydecine Innovations Group Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $14.97 Million | +23.45% |
| 2023-12-31 | $12.13 Million | +15.49% |
| 2022-12-31 | $10.50 Million | +42.49% |
| 2021-12-31 | $7.37 Million | +23.43% |
| 2020-12-31 | $5.97 Million | +2481.27% |
| 2019-12-31 | $231.30K | -87.46% |
| 2018-12-31 | $1.84 Million | +20.42% |
| 2017-12-31 | $1.53 Million | +16.03% |
| 2016-12-31 | $1.32 Million | -59.50% |
| 2015-12-31 | $3.26 Million | +69.81% |
| 2014-12-31 | $1.92 Million | +91.78% |
| 2013-12-31 | $1.00 Million | -67.11% |
| 2012-12-31 | $3.04 Million | -- |